Epidermal growth factor (EGF) and its structurally related proteins are implicated in the developmental regulation of various brain neurons, including midbrain dopaminergic neurons. There are EGF and EGF receptor abnormalities in both brain tissues and blood from schizophrenic patients. We administered EGF to neonatal rats to transiently perturb endogenous EGF receptor signaling and evaluated the neurobehavioral consequences. EGF-treatment-induced transient impairment in tyrosine hydroxylase expression. The animals grew normally, exhibited normal weight increase, glial growth, and gross brain structures, and later lost the tyrosine hydroxylase abnormality. During and after development, however, the rats began to display various behavioral abnormalities. Abnormal sensorimotor gating was apparent, as measured by deficits in prepulse inhibition of acoustic startle. Motor activity and social interaction scores of the EGF-treated animals were also impaired in adult rats, though not in earlier developmental stages. In parallel, there was a significant abnormality in dopamine metabolism in the brain stem of the adult animals. Gross learning ability appeared to be normal as measured by active avoidance. These behavioral alterations, which are often present in schizophrenic models, were ameliorated by subchronic treatment with clozapine. Although the molecular and/or physiologic background(s) of these behavioral abnormalities await further investigation, the results of the present experiment indicate that abnormal EGF receptor stimulation given during limited neonatal stages can result in severe and persistent cognitive/behavioral dysfunctions, which appear only in adulthood.
Introduction
Epidermal growth factor (EGF) was initially identified as a potent mitogenic peptide. 1 This factor also has various nonmitogenic activities, including regulation of cellular migration and differentiation. 2, 3 In the central nervous system, EGF enhances survival and promotes the differentiation of neurons, particularly midbrain dopaminergic neurons. [4] [5] [6] [7] In fact, the ubiquitous presence of EGF receptors (EGFRs) in both developing and mature brain neurons supports the biological significance of the activities of EGF and/or its related molecules in postmitotic neurons. 8, 9 Studies utilizing gene-targeting or transgenic strategies to study the EGF gene family have confirmed their importance in prenatal and postnatal development of brain structures as well as in monoamine pharmacology. [10] [11] [12] [13] Transforming growth factor (TGF)a-knockout results in partial depletion of nigral dopaminergic neurons. 11 Conversely, TGFa-overexpressing mice have abnormal monoaminergic neurotransmission and are impaired in behavioral paradigms sensitive to monoamine perturbation. 12, 13 Abnormal development of the brain is implicated in the etiology and/or pathology of various psychiatric diseases, including schizophrenia and autism. [14] [15] [16] Current evidence indicates that cytokines and growth factors can strongly influence neuronal phenotypic differentiation and subsequent neuronal function. 17, 18 We have reported that EGF levels are decreased and, conversely, that its receptor expression is upregulated in forebrain regions of postmortem schizophrenic brains. 19 Moreover, EGF levels are also decreased in the peripheral blood of young drug-free patients. 19 Although the primary molecular event, the increase in EGF or the decrease in EGFR, needs to be determined, this evidence indicates that EGF/EGFR signals are altered in both acute and chronic phases of schizophrenia and might contribute to the etiology and/or pathology of schizophrenia and its related disorders.
Many aspects of the positive behaviors of patients with schizophrenia are consistent with hyperdopaminergic neurotransmission, and can be reproduced by drugs such as amphetamines. 20 Accordingly, psychostimulant treatment has been used as an animal model of schizophrenia. 21 The behavioral abnormalities induced by psychotomimetic drugs, however, are often not as persistent as those observed in schizophrenic patients. Recently, there have been many attempts to construct an animal model of schizophrenia using transgenic or knockout mice as well as brain lesions. [22] [23] [24] [25] Although the relation between individual target genes and abnormal schizophrenia-like behaviors has been extensively investigated in such genetic models as well as in genetic linkage analyses of patients, the genetic arguments of schizophrenia are controversial. 26, 27 Rather, the most recent large epidemiologic studies place more emphasis on environmental risks for schizophrenia. 28 In the present study, we attempted to perturb endogenous EGF signaling by administering exogenous EGF to rats for a limited time period, encompassing neonatal stages, and subsequently assessed behavioral consequences in adult stages. A potentially beneficial outcome of this research is the development of new animal models for brain diseases that involve abnormal development of brain neurons.
Materials and methods

Animals
Newborn Sprague-Dawley and maternal rats were purchased from SLC (Shizuoka, Japan), and maintained under a 12-h light-dark cycle with free access to food and water. All of the animal experiments described were performed in accordance with the Animal Use and Care Committee guidelines of Niigata University.
EGF and antipsychotic treatments
Recombinant human EGF (Sigma Chemical Co, St Louis, MO, USA or Higeta-Syoyu Co, Chiba Japan) was dissolved in physiologic saline and administered subcutaneously to pups on postnatal days 2, 4, 6, 8, and 10 at the nape of the neck at a dose of 1.75 mg kg ) and clozapine (2.5 mg kg À1 day À1 ) were administered intraperitoneally in a volume of 0.2 ml per 100 g body weight on postnatal days 30-50 (ie, over a 3-weeks period).
Immunoblot analysis
Protein extracts were prepared from the brains of EGF-treated rats or control rats on postnatal day 2 or day 11. For immunoprecipitation, each brain was homogenized in a 10 Â volume of lysis buffer (50 mM Tris-HCl buffer (pH 7.4) with 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1 mg ml À1 aprotinin, 1 mg ml À1 leupeptin, 1 mg ml À1 pepstatin, 1 mM Na 3 VO 4 , and 1 mM NaF). Alternatively, tissue was homogenized with 2 Â sodium dodecyl sulfate (SDS) sample buffer (100 mM Tris-HCl (pH 6.8) buffer, 4% SDS, 100 mM dithiothreitol, 20% glycerol, 0.0001% bromophenol blue). After centrifugation of the lysates at 14 000 rpm for 20 min, supernatants were harvested and the protein content was determined using a Micro BCA kit (Pierce Chemical, Rockland, IL, USA). Each brain lysate (1 mg protein) was incubated with 4 mg of anti-EGFR antibody (Upstate Biotechnology, Lake Placid, NY, USA) at 41C overnight. Protein G-agarose beads (100 ml; Amersham Pharmacia, Tokyo, Japan) were then added, and the mixture was incubated for 1 h. The beads carrying the bound immune complexes were pelleted at 10 000 rpm for 5 min, washed three times with the lysis buffer, and resuspended in 100 ml of 2 Â SDS sample buffer. The boiled mixture was subjected to a 7% SDS-polyacrylamide gel electrophoresis, and transferred to a nitrocellulose membrane (Schleicher and Schull, Germany) by electrophoresis. The membrane for immunoprecipitates was probed with anti-phosphotyrosine (4G10, Upstate Biotechnology) or the anti-EGFR antibody. To measure protein levels for glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), and tyrosine hydroxylase (TH), immunoblots were probed with rabbit anti-GFAP, anti-NSE (both from Chemicon International, Temecula, CA, USA), and anti-TH (Eugene Tech International, Eugene, OR, USA) antibodies, respectively. After extensive washing, the immunoreactivity on the membrane was detected using anti-mouse/goat immunoglobulin conjugated to horseradish peroxidase (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) following chemiluminescence reaction (ECL kit, AmershamPharmacia).
Enzyme immunoassay EGF levels were measured by sandwich enzyme immunoassay (EIA), as described previously. 19 In brief, blood samples were collected from neonatal 
Quantification of monoamines and their metabolites
The assay for dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), serotonin (5-HT), and 5-hydroxyindoleacetic acid (5-HIAA) was previously described. 30 The striatum and frontal cortex were dissected out and frozen on dry ice. The tissue samples were then weighed individually and stored at À801C. The samples were placed in 0.5 ml of 0.1 M perchloric acid, with 50 ng of isoproterenol added as an internal standard. After sonication, the samples were vortexed and stored at 41C for 30 min. The samples were then centrifuged and the supernatant analyzed by high-performance liquid chromatography with electrochemical detection (HPLC-ECD). The HPLC-ECD system consisted of a pump (model EP-10; EICOM, Kyoto, Japan) connected to an ODS column (model MA-5ODS; EICOM, 4.6 Â 150 mm). Samples were injected into the column with an automatic sample injector (model 231; Gilson, Middleton, WI, USA) and separated with a mobile phase of 45 mM citric acid-50mM sodium acetate buffer (pH 3.65), 285 mg l À1 octanesulfonic acid sodium salt, 0.13 mM EDTA and 13% (v/v) methanol. Detection was performed electrochemically by a thin-layer cell with a glassy carbon-working electrode (model ECD-300; EICOM). The current produced was monitored using a Chromatocorder 21 (System Instruments Ltd, Tokyo, Japan).
Histologic examinations
On postnatal day 11 or 60, rats were deeply anesthetized by inhalation of diethyl ether (Wako Pure Chemical), and killed by transcardial perfusion with 4% paraformaldehyde and 0.1% glutaraldehyde in a 0.1 M phosphate-buffered solution (pH 7.4). The brains were removed and immersed in the same fixative for 24 h. Tissues were dehydrated in a graded ethanol series and embedded in paraffin wax. Serial sections (4 mm thick) were cut from the blocked samples and stained with Klü ver-Barrera stain. An atlas of the rat brain with the anatomic terminology adopted by Swanson 31 was used to identify brain regions.
Analysis of motor activity
Spontaneous locomotor activity of EGF-and cytochrome c-treated littermates was tested under novel conditions on postnatal days 24 and 52. Young rats, ie, less than postnatal day 30 (n ¼ 15, eight males and seven females) were placed in an automated Activity Monitor (27L Â 27W Â 20 H cm, MED Associates, St Albans, VA, USA) for 10 min. Adult rats (n ¼ 10, five males and five females) were placed in an open field box (51L Â 51W Â 60 H cm) and videotaped for 10 min. These boxes were divided into nine squares by floor lines. Horizontal and vertical activity was measured as line crossings and rearing counts, respectively, for 10 min. Pharmacological effects were tested 48 h after the final injection on postnatal day 52.
Measurement of acoustic startle and prepulse inhibition of startle Acoustic startle and prepulse inhibition (PPI) responses were measured in a startle chamber (SR-Lab Systems, San Diego Instruments, San Diego, CA, USA) adapted for rats. The chosen paradigm was adapted from Braff and Geyer 32 and used to assess startle amplitude and PPI response with acoustic stimuli of 120 dB, a single prepulse interval (100 ms), and three different prepulse intensities (5, 10, and 15 dB above background noise (white noise, 70 dB)). Each rat was placed in the startle chamber and initially acclimatized for 5 min with background noise alone. The rat was then subjected to 40 startle trials, each trial consisting of one of five conditions; (i) a 40-ms 120-dB noise burst presented alone (S); (ii)-(iv) a 40-ms 120-dB noise burst following prepulses by 100 ms (20-ms noise burst) that were 5, 10, or 15 dB above background noise (ie, 75-, 80-, or 85-dB prepulse, respectively); or (v) no stimulus (N; background noise alone), which was used to measure baseline movement in the chamber. These five trial types (i)-(v) were each repeated eight times in a pseudorandom order to give 40 trials. The intertrial interval was 15 s. Each trial type was presented once within a block of five trials. Analysis was based on the mean of the seven trials (ignoring the first trial) for each trial type. The percentage PPI of a startle response was calculated as: 100À[(startle response on prepulse-pulse stimulus trialsÀno stimulus trials)/(pulse-alone trialsÀno stimulus trials)] Â 100).
Social interaction
The index for social interaction of rodents was measured according to File. 33 In brief, on postnatal day 52, rats were placed in an open field box for 10 min with an unfamiliar control rat that was housed in another cage, and was age, body weight, and gender-matched. Testing was performed under high light levels (1200 lx) and unfamiliar conditions. All testing was videotaped and scored in blind. Scoring of social interaction times was based on sniffing behaviors, defined as active chasing of the partner, shaking the nose near the partner, and contacting the partner with the nose. The inter-rater variation was 6.8% (SEM, n ¼ 3 raters) according to the above definition.
Active avoidance learning
On postnatal day 51-60, rats were given 10 sessions of two-way active-avoidance conditioning (10 trials per day). 34 Active-avoidance testing was conducted in a 50L Â 24W Â 23H cm two-way automated shuttle box (Muromachi-kiki, Tokyo, Japan) made of Plexiglas and subdivided into two virtual compartments with independently electrified stainless-steel bars as floors. The conditioned stimulus (CS) was an 80-dB tone and house light for 5 s. When the CS was on, the animals had to cross to the other side of the shuttle box apparatus (avoidance response) in order to turn the CS off and avoid the appearance of the unconditioned stimulus (US). The US, a 10-s positive halfwave constant current of 0.6-mA intensity, was initiated if the animal failed to make an escape response. The inter-trial schedule had a variable interval (ranging from 15 to 30 s). The shuttle box was connected to a computer that controlled the training schedule and scored the number of avoidance and escape responses, the latency of the responses, and the number of crossings between the two sides of the shuttle box. The shuttle box was contained within ventilated, sound-absorbing, dimly lit (400 lx) enclosures. (see Salmi et al 34 for a schematic drawing of the equipment).
Statistical analysis
All values are presented as mean 7SEM. Behavioral data were subjected to Student's t-test (for univariate analysis), one-or two-way analysis of variance (ANOVA) with repeated measures on one or more factors (for multivariate analysis), depending on the test used (eg, age, or different prepulse intensity). A probability level of Po0.05 was considered to be statistically significant. Pharmacological effects were analyzed using ANOVA followed by Scheffe's multiple comparison test.
Results
EGF can pass through the blood-brain barrier to perturb neurochemical development EGF, which is a relatively small 6000-Da peptide, is suggested to enter the brain through the blood-brain barrier and act directly on neurons. 35 After neonatal rats received the injection of EGF (1.75 mg g À1 weight), serum EGF levels reached a peak concentration (41000 ng ml À1 ) in 2 h and returned to normal concentrations (30-50 ng ml À1 ) after 6 h. We assessed phosphorylation of EGFR in the brain to confirm whether EGF acted on brain neurons after peripheral administration of this factor. EGFR phosphorylation in the brain was induced 30 min to 6 h after subcutaneous EGF injection and paralleled the changes in serum EGF levels ( Figure 1a) . Thus, peripherally administrated EGF can act over and above endogenous EGF in the brain.
EGF induces the expression of TH to enhance DA synthesis in cultured midbrain neurons. 4, 5 To confirm the neurochemical effects of exogenous EGF in the intact brain, EGF was administered subcutaneously every other day until postnatal day 10 and the same dose of cytochrome c was similarly injected into control littermates. Protein levels of TH as well as those of the neuronal and glial markers, NSE and GFAP, were determined by immunoblotting using neocortical and striatum specimens from EGF-treated rats on postnatal day 11. After peripheral EGF injections, TH immunoreactivity in the striatum was up-regulated to 140712% of the control level (n ¼ 4 rats, Po0.05 with Student's t-test) (Figure 1b ). There were no changes, however, in the frontal cortex (n ¼ 5 rats, 9873%, P ¼ 0.61) (pictures not shown). Consistent with this, striatal levels of a DA metabolite, DOPAC, were modestly elevated among several monoamines and their metabolites, as demonstrated by HPLC (Table 1) . When the animals reached adulthood 50 days after EGF administration had ceased, however, the neurochemical change in the EGF-treated rats became undetectable using the immunoblotting approach (TH; 9476% and P ¼ 0.47 in the frontal cortex and 106714% and P ¼ 0.80 in the , and 24 h after EGF injection. Brain lysates were immunoprecipitated with an anti-EGFR antibody, and precipitates were separated on 7% SDS/PAGE and transferred to a nitrocellulose membrane. Immunoblotting used an anti-phosphotyrosine antibody. Immunoblot indicates marked increases of EGFR phosphorylation at 0.5-6 h after injection. (b) Expression of TH, NSE and GFAP in neonatal 11-day rats was determined by immunoblot analysis. The brain homogenates were prepared at postnatal day 11 from the prefrontal cortex and striatum of juvenile rats into which cytochrome c (CON) and EGF was administered subcutaneously five times over 10 days. Protein was separated by SDS/PAGE, transferred to a nitrocellulose membrane, and incubated with anti-TH, anti-NSE, and anti-GFAP antibodies. The locations of their immunoreactive bands were consistent with previous reports. Half of the immunoblot is shown for display. (c) Expression of TH, NSE and GFAP in P60 rats was similarly examined by immunoblot analysis. striatum, n ¼ 4 rats each) (Figure 1c) . Consistent with this, there was no significant change in DA and 5-HT or their metabolites in the forebrain regions, or in DA and 5-HT levels in the brain stem at the adult stage. In the brain stem, however, DOPAC levels were markedly reduced by neonatal EGF treatment. At both ages, the expression of the neuronal and glial markers in the forebrain regions was similar between experimental groups.
No apparent structural abnormalities in the brains of neonatally EGF-treated rats In mice, neonatal administration of EGF accelerates eyelid opening by 5 days and incisor eruption by 2 days without any other physiological abnormalities. 29 Similar results were obtained from tests involving rats: eyelid opening and incisor eruption were accelerated by an average of 2.4 and 1.3 days, respectively. Brains from adult (postnatal day 60) rats from each treated littermate were examined histochemically with Klü ver-Barrera staining. All regions of the brains from treated rats were indistinguishable in the young and adult stages. No differences were detected in the lamination and structure of the cortex, hippocampus, striatum or cerebellum (Figure 2 ). We also examined brains from postnatal day 11, but failed to observe any structural abnormalities (data not shown). At the microscopic level, there were no apparent structural abnormalities in the brains of control or EGF-treated rats. The above findings indicate that an exogenous supply of EGF in the brain produces subtle but significant neurochemical changes, without apparent structural alterations.
Increased locomotion in adult rats treated with EGF at neonatal stages Animal models of schizophrenia induced by treatment with amphetamine or phencyclidine display increases in both locomotion and rearing, and these behaviors are correlated with the positive symptoms of schizophrenia. 36 In the present study, rearing behaviors of EGF-treated rats were scored during habituation to a new environment. 37 Motor activity was recorded over a 10-min habituation period in an open field box. In the young phase, that is, postnatal day 28, EGF-treated rats exhibited a nonsignificant trend toward less rearing and line crossing compared to their cytochrome c-treated littermates (Figure 3a) . In the adult stage (ie, postnatal day 52), however, rearing was significantly increased in the EGF-treated group (Figure 3b) .
The typical antipsychotic drug haloperidol and the atypical antipsychotic drug clozapine were tested for their ability to attenuate the hyper-rearing of EGFtreated adult rats. Injections of haloperidol (0.3 mg kg À1 , i.p.) and clozapine (2.5 mg kg À1 , i.p.) acutely produced modest sedation in control rats. Thus, we changed the drug treatment paradigms and test schedules. We administered these antipsychotics once a day over 3 weeks and tested behaviors 48 h after the last injection. Chronic treatment with haloperidol and clozapine significantly reduced the rearing behavior in EGF-treated rats as compared to that of cytochrome c-treated control animals (F[5,47] ¼ 2.79, Po0.05 with ANOVA) (Figure 3c ). In contrast, these drugs alone did not attenuate the EGFinduced hyperlocomotion as measured by line-crossing movements.
Impaired startle responses and sensorimotor gating after development Sensorimotor gating is the neural process in which inhibitory neural pathways filter multiple stimuli to allow attention to be focused on one stimulus. 32 Sensorimotor gating can be assessed as PPI of startle, which is the modulation of the startle response, following a weak prepulse. 32, 38 PPI magnitudes are decreased in several human neuropsychiatric disorders, including schizophrenia, 39 obsessive-compulsive disorder, 40 Huntington's disease, 41 and Tourette's syndrome, 42 suggesting that sensorimotor gating defects are a common neural dysfunction contributing to these disorders.
Cytochrome c-and EGF-treated littermates were tested at postnatal day 46 with different prepulse intensities (Figure 4a ). EGF-treated rats exhibited significantly lower levels of PPI than cytochrome ctreated rats at all prepulse intensities. The PPI deficit of EGF-treated rats was enhanced during develop- (Figure 4b) . In parallel, startle responses were measured in the same rats. EGF-treated rats again had greater responses to acoustic startle stimuli than control rats with increasing age (Figure 4c ). Post hoc analysis revealed significantly lower PPI levels on postnatal days 28, 30, 37, 46, 51, and 60, with significantly higher startle amplitude levels after postnatal day 28. The abnormalities in startle response and PPI were indistinguishable between the sexes (data not shown).
To test the effects of typical and atypical antipsychotics, haloperidol and clozapine were administered daily to EGF-treated rats during postnatal days 30-50. This period matched the most variable phase of PPI in EGF-treated rats, as described above. PPI was measured at postnatal day 37 (after 1 week of drug treatment) and at postnatal day 51 (after 3 weeks of treatment). Animals were subjected to measurement of PPI 23 h after the last drug administration because these antipsychotic drugs themselves acutely decreased the startle response in control animals. Administration of clozapine, but not haloperidol, to EGF-treated rats for 1 week resulted in significant recovery of PPI as measured with a 75-dB prepulse (Figure 5a ). Treatment with clozapine but not with haloperidol increased PPI levels of the EGF-treated rats, making them indistinguishable from control levels, although neither antipsychotic affected the larger startle response (Figure 5b ). After the 3-weeks clozapine administration, however, there was no attenuation of the PPI abnormality (data not shown), presumably because the rats had acquired drug resistance. 43 Impairment in social interaction and its drug sensitivity The social interaction test is based on spontaneous social interaction behaviors, such as sniffing and following between two rats, and is used to test for animal anxiety. 33 In our observations of rats in the open field box, EGF-treated rats exhibited a higher rearing count than control rats, suggesting that EGFtreated rats have a higher level of anxiety. We evaluated the effects of neonatal EGF-treatment and the effects of antipsychotics on social interaction levels, employing the most aversive condition of this test, high light level and unfamiliar conditions, under which control subjects exhibited low levels of social interaction. We videotaped both animals, and scored sniffing behaviors of the target animal against those of the partner. The EGF-treated rats displayed significant reductions in sniffing time of the unfamiliar partner relative to cytochrome c-treated/vehicle-injected controls (F[3,35] ¼ 8.3, Po0.01 with ANOVA and Po0.01 with post hoc analysis) ( Figure 6 ). The alteration in social interaction scores was not ascribed to the difference in their locomotor activities. There was no correlation between horizontal locomotion and sniffing (control; P ¼ 0.69 and r ¼ 0.14, EGF; P ¼ 0.15 and r ¼ 0.48) nor between rearing and sniffing (control; P ¼ 0.73 and r ¼ À0.11, EGF; P ¼ 0.15 and r ¼ 0.48). EGF-treated animals were pretreated with haloperidol or clozapine for 3 weeks with a time schedule similar to the test for motor activity and subjected to the social interaction test. Clozapine, but not haloperidol, attenuated the decreased sniffing time of EGF-treated rats.
Normal learning in EGF-treated rats in active avoidance test Learning in the EGF-treated rats was scored at adult stages using an active avoidance test. The ability of both cytochrome c-and EGF-treated rats to avoid electrical shock improved significantly (F[1,9] ¼ 26.6, Po0.001 with ANOVA during training) (Figure 7) , and there was no difference between cytochrome cand EGF-treated rats in the ability to escape from electrical shock (F [1, 14] ¼ 0.429, P40.5). There was also no difference between these two groups in the response latency or the number of crossings between the two sides of the shuttle box (data not shown). Thus, gross learning in the EGF-treated rats appeared to be normal in the adult stage, ruling out the possibility that fundamental brain functions were impaired.
Discussion
The present experiments revealed the surprising result that neonatal EGF treatment induces delayed behavioral changes in rats with many of the same characteristics as those of established animal models of schizophrenia. In particular, these behavioral abnormalities were expressed in the adult stage, but not the juvenile stage, and persisted for a long period of time. Most of the behavioral changes were reversed by chronic administration of an antipsychotic drug(s).
EGF-treated rats displayed striking abnormalities in rearing in the open field test, as well as sensorimotor gating, startle response, and social interaction abnormalities, but learning processes were grossly normal. Although the biological mechanisms underlying the delayed appearance of behavioral abnormalities requires further investigation, neonatal EGF treatment provides an animal model for experimental studies of abnormal development of behavioral/ cognitive brain function.
Based on the neurodevelopmental or dopaminergic hypotheses of schizophrenia, we previously assessed the contribution of EGF family members to this disease in postmortem brains and in fresh serum from schizophrenic patients and control subjects. 19 EGF protein levels were decreased specifically in the prefrontal cortex and in the striatum of patients with chronic schizophrenia. Conversely, EGFR expression was significantly elevated in the prefrontal cortex. The same phenomenon was observed in the periphery. Serum EGF levels were markedly reduced in schizophrenic patients, even in young, drug-free patients, suggesting a potential etiologic link between impaired EGF signaling and this illness. It is uncertain, however, which contribute more in this illness, the increased receptor number or the decreased ligand concentration. This finding prompted us to conduct the present experiment involving EGF perturbation. EGF administration during neonatal stages induced the up-regulation of TH and DA metabolism at neonatal stages and subsequently resulted in abnormal behaviors and cognition in adulthood. Although we also administered EGF to adult mice intravenously and evaluated acute behavioral changes in motor activity, there was no apparent behavioral alteration (T Futamura, unpublished data). These observations suggest that the chronic EGF administration affected brain development.
EGFR ligands form a family of proteins including EGF, heparin-binding-EGF-like growth factor (HB-EGF), TGFa and amphiregulin, and are implicated Figure 6 Effects of antipsychotics on social interaction in EGF-treated rats. Mean (7SEM) value of social interaction (sniffing) time in open field under high light and unfamiliar conditions for each group. Control rats were administered vehicle (CON/VEH) and EGF-treated rats were administered vehicle (EGF/VEH, n ¼ 10), haloperidol (EGF/HAL, 0.3 mg kg À1 , i.p., n ¼ 6), or clozapine (EGF/CLOZ, 2.5 mg kg À1 , i.p., n ¼ 10) for 3 weeks. Each group of rats was tested 48 h after the final injection. Asterisks indicate significant differences in performance vs CON/VEH group (**Po0.01).
Figure 7
Normal learning in EGF rats assessed by active avoidance response. Mean (7SEM) value on percent avoidance response activity in active-avoidance test for control (CON, open circle, n ¼ 10) and EGF-treated (closed triangle, n ¼ 10) rats at postnatal day 51-60. Ten sessions were performed per day. The ability of both CON and EGF rats to avoid the electrical shock improved significantly during training. There was no difference between CON and EGF groups.
in cell migration, differentiation, and proliferation in the central nervous system. [1] [2] [3] 44 EGF production declines during brain development, while expression of HB-EGF and TGFa is increased. 45, 46 In fact, EGFR are expressed on pyramidal neurons, interneurons, and glial cells in the postnatal neocortex and striatum, suggesting that they have biological actions in these cells. 47, 48 Herein, we demonstrated that peripherally administered EGF can act over and above endogenous EGF in the brain as monitored by phosphorylation of EGFR. Results from EIA support this observation. Blood EGF concentrations increased more than 100-fold in parallel with the time course of the EGFR phosphorylation. Thus, the dose of EGF used in the present study was enough to perturb endogenous EGFR signaling in the brain. In this context, HB-EGF, TGFa or amphiregulin can be used as an alternate to disturb the neonatal EGFR signaling and neurobehavioral development.
In contrast to the increase in endogenous EGFR signaling, the neuronal and glial markers, NSE and GFAP, were not influenced by EGF treatment. There were no apparent structural brain alterations in either the EGF-treated juvenile or adult stages. Both coronal and sagittal sections were prepared just after EGF treatment, as well as at the adult stage, and carefully examined using conventional histologic staining methods with Klü ver-Barrera stains. In addition, cytochemical architecture and distribution of GABAergic neurons, astroglia, microglia, and proliferating cells were assessed with immunostaining against calbindin/parvalbumin, GFAP, ED1, and bromodeoxyuridine, respectively (data not shown). Our inability to demonstrate structural abnormalities, however, might be due to subtle changes, such as synaptic construction, synaptic density, and neuronal sprouting, which cannot be detected by routine histologic procedures or light microscopy. In studies of ocular dominance column formation, neurochemical disturbance of monoaminergic function during brain development leads to persistent local structural impairments. 49 Both lesions of monoaminergic fibers and blockade of monoaminergic transmission in the developing visual cortex perturb the circuit formation of ocular dominance columns. A similar scenario has been proposed from studies of babies born to mothers taking amphetamines during pregnancy. 50 Because neurobehavioral consequences from such structural brain abnormalities often become apparent during later development, 51 more detailed structural analyses would be benefical to illuminate the neurobehavioral impairments of the EGF-treated animal.
Recently, one of the EGFR ligands, TGFa has drawn special attention as an endogenous circadian regulator. 52 This factor also stimulates the release of luteinizing hormone-releasing hormone and therefore is implicated in the neuroendocrine system. 53, 54 In spite of such biological significance of the EGFR ligands, molecular mechanisms of their activities are poorly understood. The EGFR ligands, such as EGF and TGFa enhance monoamine functions and development. [10] [11] [12] [13] Consistent with these reports, we detected an increase in TH protein and DOPAC levels in the striatum just after EGF administration. In contrast, there was the opposite change in DA metabolism at adult stages: DOPAC levels were significantly decreased in the brain stem, but not in other brain regions. There are several possible reasons for the decrease in the DA metabolite in this region; reduction in local synthesis, decreased release, downregulation of reuptake, and a reduction in monoamine oxidase. Alterations in the synthesis and release of DA can be refuted by the fact that DA levels were not altered in this region. As the metabolic reduction in monoamines at adult stages was not apparent during EGF administration, this reduction cannot be a direct action of EGF. Alternatively, the overstimulation of EGFR signaling during neonatal stages might lead to a fundamental impairment of EGFR signaling in the DA neurons that persists for life.
The neurobehavioral paradigms, PPI and locomotor activities, are both influenced by DA, 55 while social interaction scores are correlated with serotonergic tone. 56 Consistent with this, clozapine but not haloperidol, antagonists for dopamine D2 receptor and/or serotonin 5-HT2 receptor, attenuated the cognitive abnormalities. These cognitive reactions are, however, often ascribed to forebrain function. Thus, the brain region responsible for such neurobehavioral abnormalities is still controversial, and the biological significance of DA release from the somatodendritic area of the brain stem remains to be established. 57, 58 Accordingly, the cognitive and behavioral impairments of the EGF-treated animal might reflect complex neurochemical alterations, including unidentified abnormal dopaminergic and/or serotonergic signaling. In this context, it is noteworthy that perturbation of central serotonergic development also induces acceleration of eyelid opening and results in behavioral abnormalities. 59 These results together suggest a strong association between a neonatal imbalance in endogenous cytokine/growth factors and a later increased risk for development of behavioral and/or cognitive dysfunction as observed in schizophrenia or autism. While over-extrapolation of the data must be avoided, this model might help to investigate the etiology and pathophysiology of psychiatric disorders, including schizophrenia.
